Online inquiry

IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4550MR)

This product GTTS-WQ4550MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CXCR4 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001008540.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7852
UniProt ID P61073
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4550MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8718MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA HuMax-TF-ADC
GTTS-WQ8023MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GZ-402668
GTTS-WQ14445MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ510MR IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 47H4
GTTS-WQ10612MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY3300054
GTTS-WQ5990MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO 095
GTTS-WQ9432MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IPH-2201
GTTS-WQ1554MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-041
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW